News

Investors might want to bet on SelectQuote (SLQT), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces

EPR Properties (EPR) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of

Investors might want to bet on Netlist, Inc. (NLST), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates --

Ralliant (RAL) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even

GeoVax Labs Inc. (GOVX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates --

Moog (MOG.A) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell

Biorestorative Therapies, Inc. (BRTX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even

Credit Acceptance (CACC) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one

Roper Technologies, Inc. ROP continues to benefit from strength in its Application Software segment. Strong momentum across its Aderant, Deltek, Vertafore, PowerPlan and CentralReach businesses is

The Hanover Insurance Group THG is expanding its motorcycle and off-road vehicle (ORV) insurance offerings across multiple U.S. states as part of its broader strategy to strengthen its total account

As AI adoption accelerates and Big Tech ramps up spending on AI infrastructure, demand for cybersecurity solutions is expected to rise alongside it. Greater AI integration increases the need for

Alibaba Group BABA closed its fiscal 2026 with a sobering message for investors — the cost of staying relevant in the artificial intelligence (AI) era is steep, and shareholders are footing the

USA Rare Earth, Inc. USAR has achieved a key milestone with the commissioning of Phase 1a of its commercial magnet production line at the Stillwater facility in Oklahoma. The development enables

CNO Financial Group, Inc. CNO is strategically positioned for growth, supported by strong collected premiums from life and health products, rising new annualized premiums and higher fee revenues. A

Analog Devices ADI shares have jumped 57.3% year to date, underperforming the Zacks Semiconductor - Analog and Mixed industry and the Zacks Computer and Technology sector’s appreciation of 67.4% and

Pediatrix Medical Group, Inc. MD is well-poised for growth, benefiting from stronger cash collections, a favorable payer mix and higher patient acuity in neonatology. Strategic acquisitions are

Applied Materials AMAT reported second-quarter fiscal 2026 non-GAAP earnings of $2.86 per share, which beat the Zacks Consensus Estimate by 6.5%. AMAT’s second-quarter fiscal 2026 non-GAAP earnings

Corcept Therapeutics’ CORT sole marketed drug, Korlym (mifepristone), which is approved for the treatment of Cushing’s syndrome, has been witnessing steady demand. Currently, the company’s top line

Argan, Inc.’s AGX fourth-quarter performance suggests that execution is becoming more than just an operating strength — it may be turning into a competitive moat. The company’s EBITDA rose to $56

ANI Pharmaceuticals’ ANIP business is moving deeper into specialty, with Rare Disease and Brands now positioned as the primary growth driver. The first quarter of 2026 reinforced that tilt, with

Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor's dream. But for income investors, generating consistent

Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor's dream. But for income investors, generating consistent